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Paving the way to metastasis
 
Tumors must invade lymph nodes to become metastatic,
but how the tumor cells make this trip is not completely
clear. On page
 
 
 
1089, Hirakawa and colleagues show that a
tumor-derived growth factor stimulates the formation of
new lymphatic vessels in the nearby lymph node, even before
any tumor cells arrive. This suggests that the tumor may
instruct the lymph node to prepare for its arrival.
Stimulation of lymphatic growth has for some time
played second fiddle to angiogenesis. During angiogene-
sis, tumors produce factors such as vascular endothelial
growth factor-A (VEGF-A) that induce vessel growth and
thus greater nutrient supply. Recently, however, two relatives
of VEGF-A, VEGF-C and VEGF-D, have been shown to
induce lymphangiogenesis within tumors. Although earlier
studies suggested that VEGF-A could also induce lymph-
angiogenesis, this had never been shown in a tumor model
and remained controversial.
Hirakawa et al. now show that expression of VEGF-A
by skin cells causes mice to develop cancer more rapidly in
response to a chemical carcinogen. Both blood vessel and
lymphatic vessel growth were increased in VEGF-A–expressing
skin tumors, a result that was consistent with their earlier
observations that VEGF-A could induce the proliferation of
lymphatic endothelial cells in culture.
VEGF-A induced active lymphatic proliferation both within
the tumor and in the nearby lymph node, possibly explaining
the increased metastasis of VEGF-A–expressing tumors.
Lymphatic growth in the lymph node began—to the authors’
surprise—before tumor cells arrived on the scene, suggesting
that VEGF-A expression may help initiate tumor metastasis.
The angiogenic activity of VEGF-A was previously
Even before metastasis, VEGF-A induces growth of new lymphatic 
vessels (red) in the draining lymph node.
 
thought to be restricted to the immediate tumor vicinity. The
authors now suggest that VEGF-A is drained from the tumor
through both preexisting lymphatic vessels and the lymphatic
vessels it helped construct. They are now investigating relative
timing to see if tumor-localized lymphangiogenesis might be a
prerequisite for node-localized lymphangiogenesis.
 
Killer combinations for cervical cancer
 
Certain combinations of HLA class I genes 
and natural killer (NK) cell receptors increase 
the risk of developing cervical cancer, 
according to a study by Carrington and 
colleagues on page 1069. Women who 
possess HLA alleles that engage inhibitory 
NK cell receptors were less likely to develop 
cervical cancer, suggesting that NK cell 
activation may promote cancer 
development.
Most cervical cancers (
 
 
 
95%) are 
associated with human papillomavirus 
(HPV), which establishes chronic infections 
in the genital tract. HPV infections that do 
not result in cancer may be due to effective 
cellular immune responses that limit HPV 
replication. NK cells are found in HPV-
positive cervical lesions and may help 
protect against the virus.
NK cell activation hinges on a balance 
between activating and inhibitory signals 
generated in part by a diverse group of NK 
cell receptors—killer cell immunoglobulin-
like receptors (KIRs)—that bind HLA class I 
molecules on interacting cells. Combinations 
of KIR and HLA genes that promote either 
NK cell activation or inhibition have been 
associated with increased susceptibility to 
various viral and autoimmune diseases.
Carrington and colleagues found that 
individuals whose HLA molecules primarily 
bound to inhibitory KIRs had a decreased risk 
for cervical cancer; those with certain 
activating HLA-KIR combinations had 
increased risk. NK cell activation may 
contribute to local inflammation, suggests 
Carrington, which has been associated with 
the progression of other types of cancer, 
including gastric and prostate cancer. But 
how NK cell activation might promote 
transformation remains unknown.
KIR–HLA combinations that result in strong activation correlate with increased risk for 
cervical cancer.
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The way to the skin
 
Memory CD4
 
 
 
 T cells express characteristic adhesion 
molecules and chemokine receptors that dictate 
their recirculation to the tissue in which they first 
encountered antigen. On page 1045, Baekkevold
and colleagues show that T cells may compete for 
access to the skin and only gain entry if they express 
the CC-chemokine receptor-4 (CCR4).
Previous studies showed that skin-homing and 
gut-homing CD4
 
 
 
 T cells express distinct chemokine 
receptors—CCR4 for skin-homing cells and CCR9 for 
gut-homing cells—and this was mirrored by the 
expression of the corresponding chemokine ligand in 
local blood vessels. The authors thus proposed that 
expression of CCR4 was required for T cells to access 
the skin (and CCR9 for the gut) but were perplexed 
by the phenotype of CCR4-deficient mice, which had 
normal numbers of skin-homing T cells.
Another skin-specific chemokine receptor may 
have compensated for the absence of CCR4. To 
test this, Baekkevold et al. staged a competition 
between wild type and CCR4-deficient bone 
marrow cells in lymphocyte-deficient mice. They 
found that CCR4
 
 
 
 cells were highly enriched 
among lymphocytes that trafficked to the skin, 
particularly during skin inflammation. This 
suggested that CCR4, although not essential, 
facilitated the generation of the skin-homing 
memory T cell population.
Recent studies have shown that tissue-specific 
dendritic cells (DC) impart CD8
 
 
 
 T cells with specific 
homing instructions and the authors suspect that a 
DC-derived signal may trigger CCR4 expression and 
similarly instruct CD4
 
 
 
 T cells.
 
Overstimulated and ineffective
 
CD4
 
 
 
 T cells become ineffective if repeatedly stimulated through
their T cell receptors (TCRs), according to a study by Jelley-Gibbs
and colleagues on page 1101. The functional demise of these cells
may help explain why persisting pathogens, such as 
 
Mycobacterium tuberculosis
 
and HIV, are associated with ineffective CD4
 
 
 
 T cell responses during the
chronic phase of infection.
Chronic infections have been shown to induce exhaustion or functional
unresponsiveness in cytotoxic CD8
 
 
 
 T cells, but their effect on CD4
 
 
 
T helper cells has not been well studied. Jelley-Gibbs et al. now show
that repeated stimulation of CD4
 
 
 
 T cells generated effector cells that
were more activated, based on the expression of activation markers
CD69 and CD62L, than cells stimulated only once but that secreted
lower levels of the cytokines interferon-
 
 
 
 (IFN-
 
 
 
) and interleukin-4
(IL-4). These repeatedly stimulated cells could not provide help to anti-
body-producing B cells, nor could they protect against influenza virus
infection when transferred into mice.
The decreased function of these repeatedly stimulated cells could
not be explained by the down-regulation of their TCRs, whose levels
were only marginally affected by the multiple rounds of stimulation.
The authors are now studying chromatin remodeling at the IFN
 
 
 
 and
IL-4 loci for possible clues to the decreased cytokine production.
CD4  T cells that undergo multiple rounds of stimulation (Th1RS) are unable to 
protect mice against influenza infection.
 
Controlling unruly osteoclasts
 
Monocytes beget macrophages, and fused macrophages beget bone-resorbing osteoclasts. Factors such 
as monocyte-colony stimulating factor (from stromal cells) and interleukin-1 (IL-1; from macrophages) 
keep this process ticking along, but now Li and colleagues report (page 1169) that osteoclasts make a 
protein that forms part of a critical feedback loop. Without the IRAK-M (IL-1 receptor associated kinase 
M) protein, which was previously thought to be expressed only in macrophages, osteoclasts are 
hyperactivated and mice get severe osteoporosis.
Bone maintenance depends on the coordination of bone formation by osteoblasts and bone resorption 
by osteoclasts. Li et al., prompted by the description of IRAK-M as a macrophage-specific inhibitor of signals 
from the IL-1 and Toll-like receptors, examined the function of this protein in osteoclasts. They found that 
mice lacking IRAK-M had increased numbers of osteoclasts, which lived longer and were more responsive to 
growth factor-derived activating signals. IRAK-M–deficient mice developed severe osteoporosis.
The osteoclast growth factor RANKL (receptor activator of the NF-
 
 
 
B ligand) turns on IRAK-M 
expression; IRAK-M then may inhibit osteoclast differentiation and activation by inhibiting IL-1–
dependent signals. IRAK-M also inhibits the fusion process that produces osteoclasts. Genetic 
mutations that cause aberrant activation of the RANKL signaling pathway have been identified in 
some cases of severe, inherited osteoporosis—the authors think IRAK-M mutations might be to 
blame for other unexplained cases.
The absence of IRAK-M 
(bottom) causes severe 
osteoporosis in mice.
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